Introduction
Learning from the history is something that we should continue over the generations. Thorium dioxide suspension, trade name "Thorotrast", used to be considered an apparently innocent contrast medium that was used for angiography with adequate radiodensity and no significant acute or subacute adverse reactions at the clinical standard in the past. However, it was an alpha emitter which was deposited in the reticuloendothelial system, including the liver, spleen and lymph nodes, and it irradiated such organs for a lifelong period [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Presented here is a tragic case that may be known to radiologists of older generations, but such experiences may not have been shared by younger radiologists, since almost all victims of Thorotrast injection are now dead. Although we will not see this type of case any more, we believe we should document historically important issues that may help shape our future practice.
Dr. Kihachiro Komiyama deceased (contribution to survey of the literature and advice).
After autopsy, liver, pancreas and spleen were inspected and radiographed. The liver weighed 3000 g, and was spongy. The average weight of the liver in Japanese adults is 1262 g in men and 1147 g in women. Therefore, the patient's liver weighed much more than normal, because the liver harbored a tumor.
There were esophageal varices. Ascites, 600 ml, was hemorrhagic. The spleen weighed 12 g, and was fibrosed Fig. 1 Plain radiographs of the abdomen. a The liver is enlarged and increased in density. The right costophrenic angle is obscured. There is an increased density in the region of the spleen (arrow). b The increased density in the spleen suggests Thorotrast deposition in the atrophic spleen (arrow). The "dog's ear sign" in the pelvic region is suggestive of ascites Fig. 2 CT of the liver. a-c Non-enhanced CT of the upper abdomen shows a large round low density mass, containing some irregular streaky densities inside the mass, in the right lobe of the liver, and scattered small low density spots in both lobes of the liver. In general, there are reticular high-densities in the parenchyma of the liver. Spotty high-densities are noted at the porta hepatis and around the pancreas. The spleen (arrow in b) is markedly dense and atrophic, consistent with Thorotrast deposition. d, e CT of the abdomen after intravenous administration showed irregularly enhanced foci in the round mass, consistent with a liver neoplasm. f Moderate amount of ascites is seen around the liver and atrophic. The average weight of the spleen in Japanese adults is 131.5 g in men and 122.4 g in women. Therefore, the spleen was much smaller than normal.
There were reticular high densities in the liver parenchyma on organ radiographs. There were increased densities around the porta hepatis and pancreas, suggesting Thorotrast deposition in the lymph nodes. There were heavily increased densities in the region of the pancreatic head and also in the atrophic spleen (Fig. 4) . Photomicrographs of the liver showed irregular and diffuse growth of tumor cells, which were large endothelial cells with atypia ( Fig. 4a: low-power magnification, b: high-power magnification). Deposition of Thorotrast was seen as brown particles in the liver (Fig. 4c) . Heavy deposition of Thorotrast was seen in the spleen (Fig. 4d) . Immunohistochemistry of the tumor cells of the liver revealed positive CD31 and CD34 (Fig. 5a, b) . Pathological findings were consistent with angiosarcoma secondary to long-standing deposition of Thorotrast. The specimen sections of the liver were also studied for radioactivity of thorium alpha particles by autoradiography at Aichi Cancer Center, courtesy of Dr. Choichiro Kido, Director at the time. The autoradiography proved the activity of alpha particles (not shown). The concentration of Thorotrast in the liver was measured as 0.353 mg/g.
Discussion
Thorotrast is a trade name of radioactive thorium dioxide suspension, widely used in the 1930s and 1940s. It was considered to be an ideal arteriographic contrast medium due to its high radiodensity and relatively low acute and subacute complication rates. Its distribution in the body depends on the route of administration, but, if administered through an intravascular route, it stays in the reticuloendothelial system with slow alpha decay (thorium-232 → radium-228 + α; physical half-life 1.405 × 10 10 years; biological half-life estimated to be 400 years) [17, 18] . It was used widely for 2-10 million people in the world, and for 10-20 thousand people in Japan, mainly in Imperial Army hospitals [6] [7] [8] .
The case presented developed angiosarcoma of the liver, 49 years after Thorotrast injection. Malignancy associated with Thorotrast deposition is various, including malignancy in the liver, biliary tracts, hematopoietic system, lymphoma, lung, peritoneum, bone and others [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . According to Ito and his associates [15] the hepatic tumors after Thorotrast deposition comprised cholangiocarcinoma (CCA) (44 cases, 43.1 %), angiosarcoma (AS) (39 cases, 38.3 %), hepatocellular carcinoma (HCC) (16 cases, 15.7 %), triple cancers (CCA + AS + HCC) (1 case, 1 %), and double cancers (CCA + HCC) (2 cases, 2 %). Angiosarcoma of the liver, rare in the general population, is a relatively specific tumor after Thorotrast deposition.
Weber et al. [19] reported in 1995 about their experience of seeing a female patient with sudden right-sided abdominal pain. Subsequently, hepatic carcinoma induced by Thorotrast exposure was found in her body. The patient did not remember that she had received an injection of a contrast medium like Thorotrast. They concluded in saying, "This case leads us to remind recently trained clinicians of this historical pathology, which obviously will disappear with time, but must kept in mind for at least two decades, when confronted with atypical abdominal pain in elderly patients."
This is a lesson in the necessity of long-term follow-ups for a specific study or treatment, learned from an article on Thorotrast.
Conclusion
Thorotrast seemed to be an ideal contrast medium at the beginning, but keen research followed and studied the effects of long-standing radiation from Thorotrast.
In fact, several researchers [4, 17] warned radiologists to withhold or stop the use of Thorotrast and to continue the follow-up of previously studied Thorotrast recipients.
What we learn from old cases like the one we presented in this paper would be that we should continue to follow and study the sequences and results of drugs, contrast medium and techniques. 
